The IMPDH2 Knockout SK-HEP-1 Polyclonal Cells product consists of a polyclonal population of SK-HEP-1 liver adenocarcinoma cells with CRISPR/Cas9-mediated disruption of the IMPDH2 gene. This loss-of-function model enables study of guanine nucleotide metabolism without clonal selection bias, capturing diverse genetic perturbations in a relevant cancer cell background.
The parental SK-HEP-1 cell line, derived from ascitic fluid of a liver adenocarcinoma patient, is a well-characterized hepatocellular carcinoma model. It displays both epithelial and endothelial features, making it valuable for investigating tumor cell plasticity and the microenvironment. Its robust growth and metabolic relevance support hepatic cancer research.
IMPDH2 catalyzes the rate-limiting, NAD+-dependent conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP) in de novo guanine nucleotide biosynthesis. This committed step, situated within purine metabolism, is tightly regulated by upstream oncogenic signals: c-Myc, mTORC1, and E2F transcription factors drive IMPDH2 expression in response to growth factor stimuli. The XMP product is subsequently converted to GMP by GMPS, utilizing glutamine and phosphoribosyl pyrophosphate (PRPP). Downstream, IMPDH2 activity governs GDP and GTP pools, which are critical for nucleic acid synthesis and GTP-dependent signaling by small GTPases. IMPDH2 also interacts with IMPDH1, ribonucleoprotein complexes, and filament-forming proteins, indicating additional cellular roles. Disruption of IMPDH2 depletes guanine nucleotides, attenuates nucleotide-dependent processes, and impairs proliferation.
In the SK-HEP-1 liver adenocarcinoma background, IMPDH2 knockout is anticipated to severely compromise cell proliferation, as cancer cells often exhibit enhanced dependency on de novo nucleotide synthesis to fuel rapid growth. This model facilitates the dissection of hepatocellular carcinoma metabolic adaptations to nucleotide scarcity and potential identification of exploitable vulnerabilities. Moreover, because IMPDH2 is the molecular target of immunosuppressive and antiviral agents like mycophenolic acid and ribavirin, these knockout cells provide a definitive tool for evaluating drug mechanisms and resistance pathways without interference from the wild-type enzyme.
These polyclonal knockout cells are ideal for cancer metabolism studies, antiviral and immunosuppressive drug development, and investigations into nucleotide pool regulation. Relevant assays include cell proliferation assays (MTT, BrdU), GTP quantification by HPLC or enzymatic methods, metabolic flux analysis, western blotting, RT-qPCR, and drug sensitivity profiling with mycophenolic acid and ribavirin. For further details, please contact Ascent Research.
